Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer

Huang, Zida; Xu, Dandan; Zhang, F; Ying, Yan; Liu, Song

doi:10.1007/s12094-015-1479-4

Cited by 49 publications

(53 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have demonstrated that lung cancer tissue and resection margins have contained amounts of immunoreactive gastrin many times larger than intact bronchial mucosa (21). Similarly, another study revealed that serum gastrin level is a useful predictor of response to chemotherapy and survival in patients with small-cell lung cancer (29). …”

Section: Discussionmentioning

confidence: 99%

Detection of Helicobacter pylori in the Bronchoalveolar Lavage of Patients with Lung Cancer Using Real-Time PCR

Fekri

Bajgani

Shafahi

et al. 2016

Jundishapur J Microbiol

View full text Add to dashboard Cite

BackgroundLung cancer is one of the most common causes of death worldwide. Although smoking and environmental pollutants are the most important risk factors of lung cancer, the role of infectious causes should also be considered in the pathogenesis and progress of lung cancer.ObjectivesThis study examined the relationship between Helicobacter pylori and lung cancer through serology, real-time PCR, and urease tests.MethodsThis descriptive cross-sectional study was conducted on 52 adult patients with lung cancer who were selected after having their history taken and being physically examined by a pulmonologist. Then, the patients underwent a bronchoscopy, a BAL, and biopsy sampling. A urease test was run for each biopsy sample, real-time PCR was used for each BAL sample, and H. pylori serology was used for each patient’s serum.ResultsThe patients’ average age was 60.65 ± 9.15 years; 11.5% were female and 88.5% were male. The prevalence of H. pylori in lung cancer patients was 11.5% according to the BAL PCR test, 92.3% according to the serology test, and 3.8% according to the urease test.ConclusionsThe results demonstrated an association between of lung cancer and H. Pylori infection via the hypothesis of direct damage and chronic inflammation through inhalation and aspiration and the systematic immune response induced by H. pylori colonization. Helicobacter pylori, together with a host’s genetic predisposition and other environmental risk factors, could be attributed to the induction of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of Helicobacter pylori in the Bronchoalveolar Lavage of Patients with Lung Cancer Using Real-Time PCR

Fekri

Bajgani

Shafahi

et al. 2016

Jundishapur J Microbiol

View full text Add to dashboard Cite

show abstract

“…Gastrin‐releasing peptide (GRP) is a 27‐amino acid bioactive peptide that promotes the release of gastrin, which is widely distributed in the human nervous system, gastrointestinal tract and respiratory tract . Previous findings indicate that small cell lung cancer (SCLC) cells synthesize and release GRP, which participates in tumor growth and metastasis . GRP is unstable in serum (half‐life of about 2 min) and difficult to be detected.…”

mentioning

confidence: 99%

“…As the signal peptide of GRP dissociates, its 148 amino acid protein is further separated into the 27 amino acid gastrin releasing peptide and the 68 amino acid ProGRP precursor . ProGRP is used as an effective indicator in monitoring and evaluating the curative effects of drugs in SCLC …”

mentioning

confidence: 99%

“…small cell lung cancer (SCLC) cells synthesize and release GRP, which participates in tumor growth and metastasis. [3][4][5] GRP is unstable in serum (half-life of about 2 min) and difficult to be detected. As the signal peptide of GRP dissociates, its 148 amino acid protein is further separated into the 27 amino acid gastrin releasing peptide and the 68 amino acid ProGRP precursor.…”

mentioning

confidence: 99%

“…6 ProGRP is used as an effective indicator in monitoring and evaluating the curative effects of drugs in SCLC. 4,7 However, several studies have found that serum proGRP is elevated in other tumors 8,9 and some benign diseases, 9,10 and primarily associated with nephropathy. 11 Kamata's survey indicated that evaluating renal function is essential when serum proGRP is applied as a tumor marker of SCLC.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Expression and clinical value of gastrin‐releasing peptide precursor in nephropathy and chronic kidney disease

et al. 2019

View full text Add to dashboard Cite

Aim To explore whether serum pro‐gastric releasing peptide (proGRP) is elevated in nephropathy patients and evaluate the diagnostic value of proGRP in chronic kidney disease (CKD) patients. Methods A total of 498 nephropathy patients and 170 healthy were selected in Zhongshan Hospital, Medical College of Xiamen University, from February 2016 to September 2017. The clinical data of the different groups including serum proGRP, CKD grading, and other serum and urine renal function biomarkers were analyzed by group comparison, correlation analysis and receiver operating characteristic curve. Results Serum proGRP levels were significantly higher in the acute kidney injury and CKD groups compared with the other groups of kidney disease patients (P < 0.01), and increased with CKD grading (P < 0.01). Serum proGRP was substantially correlated with serum creatinine (r = 0.637, P < 0.01) and cystain C (0.837, P < 0.01). Serum proGRP had moderate correlations with urine β2‐macroglobulin (β2‐m; r = 0.587, P < 0.01) and α1‐macroglobulin (α1‐m; r = 0.557, P < 0.01). There were fair associations of serum proGRP with albumin (r = 0.10, P = 0.067), 24 h proteinuria (24 h‐TPU; r = 0.092, P = 0.099), urinary albumin/urocreatinine (uAlb/Cr; r = 0.29, P < 0.01) and urinary N‐acetyl‐β‐D‐glucosidase (r = −0.142, P < 0.01). The sensitivity of proGRP was superior to that of simplified modification of diet in renal disease (MDRD) formula in diagnosing CKD I + II (81.25% vs 66.67%), CKD III (86.42% vs 74.36%) and CKD IV (71.19% vs 69.64%), while its specificity was inferior to that of simplified MDRD formula in diagnosing CKD I + II (37.65% vs 66.97%), CKD III (56.25% vs 86.67%) and CKD IV (75.31% vs 88.46%). Conclusion Serum proGRP is elevated in acute renal injury and CKD patients and increases with CKD grading. Serum proGRP is mainly affected by glomerular filtration rate and could be used for CKD staging, although the overall diagnostic sufficiency is inferior to simplified MDRD formula.

show abstract

Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report

et al. 2020

View full text Add to dashboard Cite

Background: Combination immune checkpoint inhibitor (ICI) therapy has become the mainstay in cancer treatment, and the various antitumor effects of ICIs are being observed. Synchronous multiple primary lung cancers (SMPLCs), which simultaneously involve tumors of different histologies, are often encountered in clinical settings. In standard lung cancer treatment, an anticancer drug, usually a platinum-based drug, is administered, and this first treatment provides some antitumor effect. Thus, the initial administration of platinum-based anticancer agent may mask the detection of SMPLCs. The following case represents different antitumor effects on two different primary lung lesions during treatment with ICIs. Case presentation: A 72-year-old man was referred to our hospital for an abnormal chest shadow, and computed tomography showed masses in the left lower and right upper lungs. Transbronchial lung biopsy from the left lung tumor revealed an adenocarcinoma. Following the administration of pembrolizumab (200 mg/body over 3 weeks) as monotherapy, the tumor in the left lung rapidly reduced in size. However, the tumor in the right upper lung continued to grow. Finally, his disease was diagnosed as SMPLCs of adenocarcinoma and small cell lung cancer. Conclusion: Bilateral lung lesions considered to be intrapulmonary metastases have completely different responses to ICI treatment. It is necessary to consider a diagnosis of SMPLCs if lesions with different responses to antitumor therapy are observed.

show abstract

Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer

Abstract: This study has found that there is a potential role for ProGRP and NSE in both therapy monitoring and predicting survival in SCLC patients.

Cited by 49 publications

References 19 publications

Detection of Helicobacter pylori in the Bronchoalveolar Lavage of Patients with Lung Cancer Using Real-Time PCR

Detection of Helicobacter pylori in the Bronchoalveolar Lavage of Patients with Lung Cancer Using Real-Time PCR

Expression and clinical value of gastrin‐releasing peptide precursor in nephropathy and chronic kidney disease

Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report

Contact Info

Product

Resources

About